Replimune Group, Inc. REPL

Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.

• GlobeNewswire Inc. 2 oct

  REPLIMUNE CLASS ACTION DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Urgently Reminds Replimune Group Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 5th

  A class action lawsuit has been filed against Replimune Group Inc. for allegedly making materially false statements regarding its Biologics License Application (BLA). The lawsuit claims the company failed to disclose that FDA study design concerns were not addressed and that submitted data from an early analysis included only 40 of 400 planned patients, likely causing FDA rejection of the BLA. Investors who purchased securities between October 20, 2025 and April 10, 2026 can apply to be lead plaintiff by October 5, 2026.

  

• GlobeNewswire Inc. 15 sept

  INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL

  Pomerantz Law Firm has filed a class action lawsuit against Replimune Group, Inc. following the FDA's rejection of the company's Biologics License Application for RP1 in combination with nivolumab on April 10, 2026. The FDA cited deficiencies in clinical studies and stated the evidence did not meet approval standards. The stock price fell 19.46% on the announcement and an additional 64.29% days later, totaling an 83.75% decline from $4.76 to $1.70 per share. Investors who purchased securities during the class period have until October 5, 2026, to request Lead Plaintiff status.

  

• GlobeNewswire Inc. 15 sept

  INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – SPRY

  Pomerantz Law Firm has filed class action lawsuits against ARS Pharmaceuticals, Inc. and other companies for alleged securities fraud. ARS's stock fell 23.91% after the company failed to secure expanded insurance coverage for its epinephrine nasal spray (neffy) through CVS Caremark by the July 1, 2026 deadline. Investors have until October 5, 2026 to join the class action.

  

• GlobeNewswire Inc. 14 sept

  REPL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Replimune Group, Inc. Securities Lawsuit - Contact Levi & Korsinsky

  A securities class action has been filed against Replimune Group, Inc. for allegedly failing to disclose regulatory concerns about its RP1 trial design to shareholders. The lawsuit claims the company built its regulatory strategy around single-arm trial designs that the FDA had already questioned, including response criteria inconsistent with RECIST v1.1 standards. Investors who purchased REPL shares between October 20, 2025 and April 10, 2026 experienced significant losses, with the stock declining 84.16% during the class period.

  

• GlobeNewswire Inc. 10 sept

  Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

  A class action lawsuit has been filed against Replimune Group, Inc. alleging that the company made false and misleading statements regarding its FDA submission for RP1-104. The complaint claims Replimune failed to address FDA study design concerns and submitted data from an early analysis with only 40 patients instead of the planned 400, which likely led to BLA rejection. Investors who purchased securities between October 20, 2025 and April 10, 2026 are encouraged to join the case.